The integrated 40-gene expression profile (i40-GEP) combines tumor biology with clinicopathologic features to improve prognostic accuracy in high-risk cutaneous squamous cell carcinoma (HRcSCC).
i40-GEP categorizes patients into four risk classes, identifying those at highest risk (Class 2B) with significantly poorer 3-year metastasis-free survival.
Class 2B patients demonstrate a clear benefit from adjuvant radiation therapy (ART), supporting more personalized treatment approaches.
i40-GEP outperforms individual clinicopathologic factors in predicting metastasis and local recurrence, enabling improved clinical decision-making.
